Navigation Links
Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
Date:9/13/2013

gression of cancer, infectious disease and other life-threatening conditions. ESI's lead product, an Enzyme Linked Lectin Specific Assay (ELLSA) has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.

Dr. Taylor stated, "I am extremely excited about joining Exosome Sciences as their Chief Scientific Officer. I have been pioneering the field of exosome biology for more than 35 years and believe that exosomes represent the ideal disease marker due to their stability in the peripheral circulation and ability to be multiplexed. Exosome-based diagnostics will not only be used in identification and management of a variety of cancers, but also in other pathologies such as viral infections, pregnancy complications, birth defects, cardiovascular and neurodegenerative diseases. No other platform exhibits their potential for patient stratification and real-time monitoring of therapeutic responses. I have a long history of collaboration with scientists at Aethlon Medical and this opportunity will expand that interaction to bring ELLSA based assays to the clinic."

The release of exosomes by viable cells has been demonstrated in multiple cell types and systems.  These nano-sized vesicles are detectable in biologic fluids, including blood, urine, ascites, and pleural fluids.  They are essential mediators of normal homeostasis, based on their role in intercellular communication via surface interactions and transfer of macromolecules between cells.  Cell injury or transformation is associated with alterations in the cell's exosome production and composition of these exosomes. This aberrant exosome composition can be utilized as surrogate markers of specific disease pathologies. The ESI mission is to advance an exosome-based biomarker platform to diagnose a broad-spectrum of disease c
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical Announces Launch of Exosome Sciences Subsidiary
2. Aethlon Medical to Present at Exosomes and Circulating Biomarkers 2013 Summit
3. Aethlon Medical Announces the Appointment of Chetan S. Shah, M.D. to its Board of Directors
4. Aethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
5. Aethlon Medical (AEMD) Note: New Government Contract, Resubmission of IDE to Treat Hepatitis C (HCV), Biothreat Legislation Signed into Law by President Obama
6. Aethlon Medical (AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer
7. Aethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
8. Aethlon Medical (AEMD) Note: Since September 30th, 2011 / Thank You Shareholders
9. Aethlon Medical Discloses CEO Interview
10. Aethlon Medical (AEMD) Note: Extracorporeal Methods to Reduce Inflammation in Sepsis
11. Aethlon Medical To Present Today At The 15th International Conference On Dialysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... and ,S-HERTOGENBOSCH, The Netherlands , ... subsidiary, HealthLink International received its ISO 13485 certificate for ... and administrative services for medical device manufacturers throughout ... Rick Hughes , President of HealthLink Europe and ... 13485 certified facilities, two in Europe ...
(Date:4/1/2015)... April 1, 2015  New York College of Health ... Intellectual Properties portfolio with U.S. Patent #8,996,098 donated by ... patent represents a surgical instrument that allows surgeons to ... it were in the traditional format of a slide ... medical databases during surgery, thus providing the surgeon real ...
(Date:4/1/2015)... YORK , April 1, 2015 Morgan ... claims against the board of directors of Auspex Pharmaceuticals, ... concerning possible breaches of fiduciary duty and other violations ... Company to Teva Pharmaceuticals Industries Ltd.  The transaction is ... own shares of Auspex and would like to learn ...
Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) ... VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, ... Phase 3 studies in patients with macular edema due ... 56.1 percent of patients receiving VEGF Trap-Eye 2 milligrams ...
... N.Y., Dec. 20, 2010 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... teleconference and webcast at 8:30 a.m. Eastern Time on Monday, ... study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) ... DA VINCI study in patients with diabetic macular edema (DME). ...
Cached Medicine Technology:Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 2Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 3Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 4Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 5Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 6Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 7Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 8Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 9Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME) 2
(Date:4/2/2015)... Portsmouth, New Hampshire (PRWEB) April 02, 2015 ... the availability of ForMedical Cloud services, a comprehensive ... for use by home health care service organizations. ... a single source solution for the provisioning and ... a high quality and competitively positioned home health ...
(Date:4/2/2015)... 02, 2015 Deerfield Veterinary Hospital ... accreditation from the American Animal Hospital Association (AAHA). ... to 15 percent of veterinary practices in the ... hospitals are not required by law to be ... examined the Springfield veterinary hospital  on some ...
(Date:4/2/2015)... Atlanta, Georgia (PRWEB) April 02, 2015 ... continued the Lunch Seminar Series on March 30th ... Director of PartnerTech Inc. , a leading provider ... ‘Total Cost Thinking: Defining Total Cost vs. Piece ... late-stage configuration, agile supply chain service and other ...
(Date:4/2/2015)... “ SmartenFit ” was featured on NewsWatch ... at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... for a sustainable healthy lifestyle. , Health and fitness apps ... new application that covers health from a different angle. The ...
(Date:4/2/2015)... 02, 2015 Zapable - a new ... a quick and easy means for creating professional mobile ... creating a buzz of excitement throughout the Internet marketing ... attention of HonestyFirstReviews.com’s Tiffany Hendricks, prompting her to publish ... Andrew and Chris Fox's new Zapable software has ...
Breaking Medicine News(10 mins):Health News:ChartaCloud Introduces ChartaCares and ForMedical Cloud Services for Home Health Care 2Health News:Deerfield Veterinary Hospital Earns Renewed AAHA Accreditation 2Health News:Georgia Tech Manufacturing Institute Lunch Series Continues with Gary Bruce of PartnerTech 2Health News:Georgia Tech Manufacturing Institute Lunch Series Continues with Gary Bruce of PartnerTech 3Health News:An Application for Long Term Sustainable Lifestyle Change Was Featured on NewsWatch Television 2Health News:Zapable - Review Examining Andrew and Chris Fox’s App Building Software System Released 2
... price for a 30-second advertising spot in the 2012 Super Bowl ... study suggests that, for advertisers, it may not really matter if ... But for the sake of companies forking out big bucks on ... The study by an Oregon State University researcher, which is ...
... -- Teens who think of themselves as thrill-seekers and who ... likely to drive with other teens in the car, which ... finds. And a second study of teens involved in ... distraction and risky driving behavior often played a role. ...
... HealthDay Reporter , THURSDAY, Jan. 26 (HealthDay News) -- ... provide insight into whether patients are at high risk of ... cancer. The test, which is currently available, could ... prevent the cancer from returning. There are caveats: The ...
... a "common sense" decision to start the company in a ... belt. , "We wanted to give better stroke care," said ... of Neurology at the Medical College of Georgia at Georgia ... and his colleagues were frustrated that nearly five years after ...
... By Denise Mann HealthDay Reporter , THURSDAY, Jan. ... for liver cancer among people with hepatitis B, a new study ... hepatitis B virus, is one of the main causes of liver ... have shown promise in reducing risk for cancer. Other studies have ...
... a sensitive non-invasive marker of early lung disease in young ... from Australian researchers. "We found that LCI is elevated ... airway inflammation and Pseudomonas aeruginosa," said Yvonne Belessis, MBBS, MPH, ... may not only be a marker of early CF lung ...
Cached Medicine News:Health News:Sporting event ads viewed favorably - especially if the game is close 2Health News:Teen Driver's Friends Can Be Dangerous Distraction, Studies Find 2Health News:Test Might Predict Risk of Lung Cancer's Return 2Health News:Georgia Bio honors biotech company that enables stroke care 2Health News:Georgia Bio honors biotech company that enables stroke care 3Health News:Statins May Stave Off Liver Cancer in People With Hepatitis B 2Health News:Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: